Ovarian rejuvenation

Abstract

Bckground: Premature ovarian insufficiency (POI) occurs in 1% of cases in women aged 35 to 40 years and a large number of women of this age are faced with the problem of reduced reproductive ability or losing reproductive ability and a number of other symptoms affecting overall health and quality of life. It has been proven that many genetic and external factors lead to the Hippo signal pathway disruption and follicle growth disruption, resulting in amenorrhea and menopause. Methods: Our study provides concise summary of published data about experimental evidences for the restore of reproductive ovarian function in women with compromised reproductive health. The database used was Pubmed where full text articles and English-written reviews published between 2004 and 2018 were preferred. The MeSH (Medical Subject Headings) terms used were ‘ovarien rejuvenation’,' ovarien follicle activation’, ‘female germline stem cells’, ‘stem cell therapy’ and ‘ovarien insufficiency’, either alone or in combination. The references of the articles were also considered when searching for the most relevant articles. Results: Exposure of ovarian tissues to autologous concentrated growth factors and autologous stem cells results in the Hippo signal path disruption and stimulation of revived follicle growth and improvement of ovarian reproductive function. In vitro ovarian activation represents autologous genetic treatment of the gonadal tissue to restore reproductive and endocrine ovarian function. Among the sleepy follicles, ~ 0.1% of the follicles were selected for activation. Since patients with POIs (primary ovarian insufficiencies) have <1,000 residual follicles, growth factors and maternal cells can activate sleepy follicles. SEGOVA acts on the intracellular signaling system. The use of the SEGOVA method (ovarian in vitro activation by autologous growth factors and autologous stem cells) leads to regeneration and improvement of the reproductive function of the ovaries. Conclusion: In vitro ovarian activation represents autologous genetic treatment of gonadal tissue to restore reproductive and endocrine ovarian function. Oogenesis depends on the proper genetic control. Ovarian function is achieved by the formation of ovarian cells, which is associated with a specific hormone activity. The primitive status of primordial follicles is characterized by communication with the surrounding granulocyte cells and numerous mechanical and chemical factors that control the progression of their cell cycle. Autologous growth factors and autologous stem cell therapy activate genetic pathways, initiate, and promote the development and differentiation of ovarian cells, resulting in improved endocrine status and ovarian function.